Table of Contents Table of Contents
Previous Page  284 / 916 Next Page
Show Menu
Previous Page 284 / 916 Next Page
Page Background


25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302


Vrije Universiteit, Faculty of Behavioural and Movement Sciences,

Section Clinical Neuropsychology, Amsterdam, Netherlands


Academic Medical Centre, University of Amsterdam, Academic

Psychiatric Center, Early Psychosis Department, Arkin, Amsterdam,


Corresponding author.


In a recent placebo-controlled, double blind

crossover trial (


= 52), we found significant beneficial effects on

memory (


= 0.30) and negative symptoms (


= 0.29) after 12 weeks

memantine augmentation in patients with clozapine-refractory



In this open-label 1 year extension study, we report the

long-term effects and tolerability of memantine add-on therapy

to clozapine.


Completers of the first trial who experienced benefi-

cial effects during 12 weeks of memantine treatment received

memantine for one year. Primary endpoints were memory and

executive function using the Cambridge neuropsychological test

automated battery (CANTAB), the Positive and Negative Syndrome

Scale (PANSS), and the Clinical Global Impression Severity Scale



Of 31 RCT completers who experienced beneficial effects

from memantine, 24 received memantine for one year. The small

improvement in memory found in the memantine condition in the

placebo-controlled trial remained stable in the extension study.

Executive function did not improve. After 26 weeks of memantine

add-on therapy to clozapine, PANSS negative symptoms (


= 0.53),

PANSS positive symptoms (


= 0.50), and PANSS total symptoms



= 0.54) significantly improved. Even further significant improve-

ment in all these measures was observed between 26 weeks and 52

weeks memantine, with effect sizes varying from 0.39 to 0.51. CGI-

S showed a non-significant moderate improvement at 26 weeks



= 0.36) and 52 weeks (


= 0.34). Memantine was well tolerated

without serious adverse effects.


In the one-year extension phase, the favorable effect

of adjunctive memantine on memory was sustained and we

observed further improvement of positive, negative and overall

symptoms of schizophrenia.

Disclosure of interest

P.F.J.S. reports personal fees from H. Lund-

beck A/S, outside the submitted work and he is a board member

of the Dutch Clozapine Collaboration Group. L.d.H., has received

investigator-led research grants or recompense for presenting his

research from Eli Lilly, Bristol-Myers Squibb, Janssen-Cilag and



Efficacy and tolerability of

aripiprazole intramuscular as

maintenance treatment in patients

with paranoid schizophrenia

B. Serván

, A. Montes , M. Machín , P. Gómez , J. García-Albea ,

S. González , J. Ibá˜nez , M.D. Morón

Hospital Clinico San Carlos, Psychiatry, Madrid, Spain

Corresponding author.


Patients suffering from paranoid schizophrenia,

require long-term anti-psychotic treatment, which provide, in

addition to adequate efficacy both positive and negative symptoms,

a good safety and tolerability profile that would ensure adequate

adherence to prevent relapse.


To analyze the efficacy, tolerability and therapeutic

adherence over a year after the introduction of aripiprazole depot in

patients diagnosedwith paranoid schizophrenia previously treated

with other oral or depot anti-psychotics

[1,2,3] .


One-year prospective longitudinal study with a sam-

ple size of 23 patients diagnosed with schizophrenia in outpatient

treatment. Study variables (baseline, 6 and 12months): Brief Psy-

chiatric Rating Scale (BPRS), clinical global impression (CGI), mean

dose of aripiprazole depot, previous treatments, adherence, relapse

rate, prolactin levels, sexual dysfunction, BMIs.


Twenty-three patients (71%men, 29%women) diagnosed

with paranoid schizophrenia were identified. Improvement was

obtained in the different study variables with statistically signif-

icant difference (




Following the introduction of aripiprazole depot in

patients diagnosed with schizophrenia previously treated with

other oral or depot anti-psychotics in our study, we conclude that

maintaining therapeutic efficacy a better tolerability and safety

profile, better therapeutic adherence and consequently lower

relapse rate were achieved.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


[1] Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular

depot as maintenance treatment in patients with schizophre-

nia: A 52-week, multicenter, randomized, double-blind,

placebo-controlled study. J Clin Psychiatry 2012;73(5):617–24.

[2] Matt Shirley, CarolineM, Perry, Aripiprazole:. AReviewof Its Use

as Maintenance Treatment for Adult Patients with Schizophre-

nia. Drugs 2014;74:1097–110.

[3] Fleischhacker WW. Aripiprazole once-monthly for treatment

of schizophrenia: double-blind, randomised, non-inferiority

study. Br J Psychiatry 2014;205(2):135–44.


Devaluation towards people with

schizophrenia in Italian medical,

nursing, and psychology students

L. Sideli

, A.U

. Verdina , F. Seminerio , M.V. Barone , C. La Cascia ,

C. Sartorio , A. Mule , C. Guccione , D. La Barbera

Section of Psychiatry, Experimental Biomedicine and Clinical

Neuroscience, Palermo, Italy

Corresponding author.


Discrimination towards people with schizophrenia

(PWS) by healthcare professionals is responsible of underdiagnosis

and undertreatment of these patients. Negative attitudes toward

PSW in health care professionals tend to be present since their uni-

versity studies and are related to their knowledge and experience

about the disease.

Objectives and aims

To assess opinion towards PSW in medical,

nursing and psychology students and to investigate the relation

with their knowledge of schizophrenia and its causes.


The study involved 133 medical, 200 nursing and 296

psychology undergraduate students. The opinion on mental illness

questionnaire, the Devaluation Consumers Scale, and the Devalua-

tion of Consumer Families Scale were administered to the sample.

ANOVA and ANCOVA were used to test differences between groups

and the relation between causal explanation of schizophrenia and

discrimination towards PWS.


Psychology students were more aware than the other

student of public stigma towards PWS and their families (




< 0.001;




< 0.001) and expressed a more positive view on

treatments’ effectiveness (




< 0.001). Psychology (OR 0.48,

95% CI 0.26–0.88) and nursing (OR 0.29, 95% CI 0.15–0.55) students

were more likely to identify psychological and social risk factors as

more frequent causes of schizophrenia (vs. biogenetics) and these,

in turn, were related to a better opinion towards social equality of



These preliminary findings underline the relevance

of biopsychosocial model of schizophrenia within stigma-

reduction programs for health science students.